S&P Futures
5,896.25 0.00 (0.00%) Dow Futures
43,155.00 -22.00 (-0.05%) Nasdaq Futures
20,516.25 -3.25 (-0.02%) Russell 2000 Futures
2,253.00 -2.50 (-0.11%) Crude Oil
70.54 -0.02 (-0.03%) Gold
2,735.20 -3.70 (-0.14%)
Replimune Group, Inc. (REPL)
After hours:
| Previous Close | 11.53 |
| Open | 11.44 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 11.09 - 11.59 |
| 52 Week Range | 4.92 - 15.18 |
| Volume | |
| Avg. Volume | 686,240 |
| Market Cap | 775.448M |
| Beta (5Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
Morgan Stanley's Strategic Reduction in Replimune Group Inc Holdings
On September 30, 2024, Morgan Stanley executed a significant transaction involving the sale of 192,770 shares in Replimune Group Inc (NASDAQ:REPL), a clinical-stage biotechnology company. This move reduced Morgan Stanley's holding by 11.11%, leaving the firm with a total of 1,542,884 shares. Despite the reduction, Morgan Stanley maintains a 2.30% position in REPL, reflecting a strategic adjustment rather than a complete exit.
- Simply Wall St.
Replimune Group, Inc. (NASDAQ:REPL) Shares Could Be 48% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Replimune Group fair value estimate is US$23.01 Replimune...
- Pharmaceutical Technology
Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy
Replimune has announced the first patient in the Phase III melanoma trial with its lead immunotherapy RP1 or vusolimogene oderparepvec has been dosed and randomised. The IGNYTE-3 study (NCT06264180) will investigate the use of RP1 plus Bristol Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab) for patients with advanced melanoma who have progressed on anti-PD1 and anti-CTLA-4…
